

**Amendments to the Claims:**

No claim is amended. This listing of claims is provided for reference:

**Listing of Claims:**

1. - 21. (Cancelled)

22. (Previously presented) An isolated nucleic acid encoding an antibody, wherein the antibody binds to ErbB3 protein and reduces heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3.

23. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody further increases the binding affinity of heregulin for ErbB3 protein.

24. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody further reduces heregulin-induced ErbB2 activation in the cell.

25. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody is a monoclonal antibody.

26. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody is humanized.

27. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody is human.

28. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody is an antibody fragment comprising an antigen binding region.

29. (Previously presented) The isolated nucleic acid of claim 28 wherein the antibody fragment is a Fab.

30. (Previously presented) An isolated nucleic acid encoding an antibody, wherein the antibody binds to ErbB3 protein and increases the binding affinity of heregulin for ErbB3 protein.
31. (Previously presented) An isolated nucleic acid encoding an antibody, wherein the antibody binds to ErbB3 protein and reduces heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
32. (Previously presented) An isolated nucleic acid encoding an antibody, wherein the antibody binds to ErbB3 protein and reduces heregulin binding thereto.
33. (Previously presented) The isolated nucleic acid of claim 32 wherein the antibody further reduces heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
34. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody binds to the epitope bound by the 8B8 antibody (ATCC HB-12070).
35. (Previously presented) The isolated nucleic acid of claim 22 wherein the antibody has the complementarity determining regions of the 8B8 antibody (ATCC HB-12070).
36. (Previously presented) A vector comprising the isolated nucleic acid of claim 22.
37. (Previously presented) A host cell comprising the isolated nucleic acid of claim 22.
38. (Previously presented) A method for making an antibody comprising culturing the host cell of claim 37 so that the nucleic acid is expressed and recovering the antibody from the host cell culture.
39. (Previously presented) The method of claim 38 further comprising conjugating the recovered antibody with a cytotoxic agent or enzyme.
40. (Previously presented) A vector comprising the isolated nucleic acid of claim 30.

41. (Previously presented) A host cell comprising the isolated nucleic acid of claim 30.
42. (Previously presented) A method for making an antibody comprising culturing the host cell of claim 41 so that the nucleic acid is expressed and recovering the antibody from the host cell culture.
43. (Previously presented) The method of claim 42 further comprising conjugating the recovered antibody with a cytotoxic agent or enzyme.
44. (Previously presented) A vector comprising the isolated nucleic acid of claim 31.
45. (Previously presented) A host cell comprising the isolated nucleic acid of claim 31.
46. (Previously presented) A method for making an antibody comprising culturing the host cell of claim 45 so that the nucleic acid is expressed and recovering the antibody from the host cell culture.
47. (Previously presented) The method of claim 46 further comprising conjugating the recovered antibody with a cytotoxic agent or enzyme.
48. (Previously presented) A vector comprising the isolated nucleic acid of claim 32.
49. (Previously presented) A host cell comprising the isolated nucleic acid of claim 32.
50. (Previously presented) A method for making an antibody comprising culturing the host cell of claim 49 so that the nucleic acid is expressed and recovering the antibody from the host cell culture.
51. (Previously presented) The method of claim 50 further comprising conjugating the recovered antibody with a cytotoxic agent or enzyme.